JOHN STUART PATTON
CIK 1247653 · Chief Scientific Officer · last filed 2014-08-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.45M
Companies
2
Total Filings
38
Lifetime Open-Market Net
-$4.96M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Director | 179,876 | — | — | -$4.96M | 30 | 2014-08-21 |
| NKTR | Chief Scientific Officer | 20,976 | $69.36 | $1.45M | -$3.3K | 8 | 2008-11-18 |
Recent Filings · Page 2 of 4
38 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2007-12-26 | NKTR | Grant (A) | — | $0 | EDGAR |
| 2007-10-18 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Sell (S) | −15,000 | -$135.6K | EDGAR |
| 2007-10-11 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Sell (S) | −15,000 | -$130.3K | EDGAR |
| 2007-10-02 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Sell (S) | −15,000 | -$133.5K | EDGAR |
| 2007-09-26 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Sell (S) | −15,000 | -$134.1K | EDGAR |
| 2007-09-19 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Sell (S) | −17,471 | -$156.0K | EDGAR |
| 2007-07-11 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Sell (S) | −20,000 | -$195.7K | EDGAR |
| 2007-06-26 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Sell (S) | −8,200 | -$73.6K | EDGAR |
| 2007-06-26 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Sell (S) | −11,800 | -$102.2K | EDGAR |
| 2007-06-19 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Sell (S) | −20,000 | -$205.1K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.